This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
Biomarker Research Open Access 17 June 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ossenkoppele G, Schuurhuis GJ . MRD in AML: time for redefinition of CR? Blood 2013; 121: 2166–2168.
Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M . Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008; 14: 7161–7166.
Anguille S, Van Tendeloo VF, Berneman ZN . Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26: 2186–2196.
Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Gotz M et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012; 120: 1282–1289.
Greiner JSV, Schmitt M, Götz M, Döhner K, Wiesneth M, Döhner H et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 2013; 122: 1087–1088.
Hofmann S, Gotz M, Schneider V, Guillaume P, Bunjes D, Dohner H et al. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol 2013; 31: e44–e47.
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.
Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2010; 116: 3907–3922.
Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012; 119: 3571–3577.
Vignali DA, Kuchroo VK . IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722–728.
Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 2010; 133: 99–105.
Majeti R . Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 30: 1009–1019.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
Alharbi RA, Pettengell R, Pandha HS, Morgan R . The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 2013; 27: 1000–1008.
Acknowledgements
This work was supported by grants from the German Research Foundation (DFG GR2676/3-1) and the Else Kröner-Fresenius Stiftung (2011-A63).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author contributions
VS, LZ, JG and SH designed the study and wrote the manuscript, VS, LZ, JG, LB and TB analyzed the data, VS, LZ, MR, MG, AL and UB performed the experiments, MW, KD, HS and HD provided advice on the study.
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Schneider, V., Zhang, L., Bullinger, L. et al. Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. Leukemia 28, 1759–1762 (2014). https://doi.org/10.1038/leu.2014.116
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.116
This article is cited by
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
Biomarker Research (2023)
-
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications
Leukemia (2015)